All In Biotech

Drug Trial Radar · NCT00081497

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Multi-Center, Open-Label Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease That Previously Participated in the AGAL-008-00 Study

Last checked: Nov 20, 2026Latest source record: Apr 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

67

Actual

Start

Jan 2004

Primary completion

Sep 2005

Study completion Sep 2005

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Apr 16, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People with Fabry Disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme. Fabrazyme (agalsidase beta) is a drug that helps to break down and removes certain types of fatty substances called "glycolipids". These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid (globatriaosylceramide or GL-3) levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study analyzed the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease that previously participated in the AGAL-008-00 (NCT0074984) study.

Conditions

  • Fabry Disease

Interventions

  • agalsidase betaBiological

    1.0 mg/kg every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in Inverse Serum Creatinine Within Patients' Slopes Between the Placebo AGAL-008-00 (NCT00074984) and Fabrazyme AGAL02503 (NCT00081497) PeriodsTime frame: Placebo period AGAL-008-00 (up to 35 months) through Fabrazyme period AGAL02503 (18 months)

Locations

25 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of San Francisco

    San Francisco, California

  • University of Connecticut Health Partners

    West Hartford, Connecticut

  • Oncology Hematology Association

    Coral Springs, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Children's Memorial Hospital

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Gene Therapy Center - Department of Pediatrics and Institute of Human Genetics

    Minneapolis, Minnesota

  • Children's Hospital

    Buffalo, New York

  • Mount Sinai School of Medicine

    New York, New York

  • University of Rochester School of Medicine

    Rochester, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • University of Washington School of Medicine

    Seattle, Washington

  • Queen Elizabeth II Health Center

    Halifax, Nova Scotia, Canada

  • North York General Hospital

    Toronto, Ontario, Canada

  • Hopital du Sacre-Coeur de Montreal

    Montreal, Quebec, Canada

  • University Hospital

    Prague, Czechia

  • Sopron Megyei Jogu Varos Erzsebet Korhaz

    Sopron, Hungary

  • Klinika Chorob Metabolicznych Instytut

    Warsaw, Poland

  • Hope Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.